Sight Sciences, Inc.

Sight Sciences reported FY 2025 revenue of $77.4 million, generating a gross profit of $66.7 million. The company incurred a net loss of $38.4 million, an improvement from a net loss of $51.5 million in FY 2024. Operating expenses totaled $103.8 million, primarily driven by selling, general and administrative costs of $89.2 million. The company ended the year with $92.0 million in cash and cash equivalents, total assets of $115.3 million, and long-term debt of $40.3 million. Key forward-looking challenges include dependence on OMNI and TearCare product revenue, ongoing reimbursement uncertainties with Medicare Administrative Contractors, and significant reliance on manufacturing in China subject to tariffs.

Key Takeaways